Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 176 - 200 of 4338 in total

Alemtuzumab

Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a...
Approved
Investigational
Matched Description: … The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and ... recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell ... [L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic …

Canagliflozin

Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018...
Approved

Lovotibeglogene autotemcel

Lovotibeglogene autotemcel consists of autologous hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modified β-globin gene. Specifically, lovotibeglogene autotemcel provides a functional copy of a modified beta-globin gene (βA-T87Q-globin) that when combined with α-globin, produces hemoglobins with similar oxygen-binding capacity as wild type hemoglobin. Additionally,...
Approved
Investigational
Matched Description: … lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell ... exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based …
Matched Categories: … Autologous Cultured Cell ... Autologous Hematopoietic Stem Cell-Based Gene Therapy …

Pozelimab

CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement...
Approved
Investigational
Matched Description: … [A261120] Pozelimab is a human, monoclonal immunoglobulin G4P antibody against the terminal …

Ixazomib

Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to...
Approved
Investigational

Amphetamine

Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first...
Approved
Illicit
Investigational

Berdazimer

Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors. It releases NO through exposure to proton donors like water, which will degrade the N-diazeniumdiolate entity. Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous...
Approved

Tafasitamab

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19...
Approved
Investigational
Matched Description: … made it a desirable target in the treatment these B-cell malignancies. ... Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell ... leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))[L15302] has …
Matched Categories: … Lymphoma, B-Cell …

Sildenafil

In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to...
Approved
Investigational

Cefapirin

Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.
Approved
Vet approved

Lubiprostone

Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. Activation of these channels promotes the secretion of a chloride-rich fluid that soften...
Approved
Investigational

Retifanlimab

Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. Other monoclonal...
Approved
Investigational
Matched Description: … By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune ... retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell …
Matched Categories: … PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors …

Tinidazole

A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.
Approved
Investigational

Alpelisib

Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target...
Approved
Investigational
Matched Description: … epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer ... Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human ... is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human …
Matched Categories: … Breast Neoplasms …

Albiglutide

Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the...
Approved
Matched Description: … It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. …

Triethylenetetramine

Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, spermidine and spermine. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985...
Approved
Investigational

Tislelizumab

Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated...
Approved
Investigational
Matched Description: … [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through …
Matched Categories: … PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors …

Selumetinib

Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However,...
Approved
Investigational

Lorlatinib

Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive...
Approved
Investigational
Matched Description: … third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell ... in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell …

Dobutamine

A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Approved

Naxitamab

Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within...
Approved

Glofitamab

Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.[L45698,A258488] Glofitamab was approved...
Approved
Investigational
Matched Description: … Canada in March 2023 for the treatment of certain patients with relapsed or refractory diffuse large B-cell ... for patients having failed other systemic therapies or for whom targeted therapies - such as CAR-T cell ... for the treatment of patients with relapsed or refractory DLBCL not otherwise specified or large B-cell …

Azficel-T

Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. Dermal fibroblasts are collected from the post-auricular biopsy tissue and aseptically expanded using standard tissue-culture procedures until sufficient cells for three doses are obtained [FDA Label]....
Approved
Investigational
Matched Description: … Expanded cells are then suspended in a cell medium. …
Matched Categories: … Autologous Cultured Cell …

Tocofersolan

D-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis . Cholestasis is the reduction or stoppage of bile flow, either to impaired secretion by hepatocytes (liver cells) or obstruction , . Tocofersolan is a...
Approved

Pemetrexed

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for...
Approved
Investigational
Matched Description: … Its use in non-small cell lung cancer has also been investigated. …
Displaying drugs 176 - 200 of 4338 in total